Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy
This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations. These EGFR inhibitors exhibit therapeutic potential for the treatment of nonsmall cell lung cancer (NSCLC) and other malignancies driven by EGFR mutations.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Yanwei Jiang
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00030
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00